Weave Bio is expanding its collaboration with Takeda to deploy its AI-native regulatory automation platform across 14 active drug-development programs in multiple global markets, the companies announced Tuesday.

 

The collaboration is aimed at accelerating some of the most time-intensive regulatory work in drug development, combining Weave’s artificial intelligence capabilities with Takeda’s regulatory expertise.

 

“Regulatory communications are the most knowledge-intensive workflows in all of drug development, and for too long that knowledge has lived in static documents that are hard to find, cumbersome to manage, and nearly impossible to maintain over time,” said Brandon Rice, CEO and co-founder of Weave Bio. 

 

"Takeda came to this partnership with deep regulatory expertise, pressing needs, and a genuine commitment to collaborative innovation. What we've built together demonstrates how AI-assisted regulatory workflows may evolve across the industry.”

 

The partnership initially focused on AI-assisted preparation of Investigational New Drug (IND) submissions before expanding to Health Authority Question (HAQ) and Response to Question (RTQ) workflows.

 

Results from the IND phase, detailed in a research paper co-authored by scientists from Weave and Takeda, point to substantial reductions in regulatory-writing time. In the evaluated use case, time to first draft fell by about 97% — from roughly 100 hours to three hours — while the overall timeline was compressed by 60%.

 

The study also reported approximately 95% faithfulness to source data under its methodology.

 

The companies say the technology is now being used for HAQ and RTQ workflows as well. More than 100 questions have been processed, with no extraction errors identified in the evaluated dataset. AI-generated answers received an average quality score of 68%, compared with a target range of 50% to 70%.

 

“Takeda is working to become a leader in the responsible application of AI across every area of R&D, helping our teams work more effectively and accelerate the delivery of innovative medicines to patients,” said Nahid Latif, Chief Regulatory Officer, Head of Global Regulatory Affairs, Takeda. 

 

“Our collaboration with Weave is an important example of this ambition in action, enabling us to implement AI-driven regulatory workflows while ensuring that regulatory professionals retain responsibility for content, verification and final decision-making.”

 

The expansion comes as drug regulators sharpen their expectations around the use of AI in pharmaceutical development and regulatory processes. Those expectations increasingly emphasize risk-based oversight, lifecycle management, validation and human accountability.

 

The FDA issued draft guidance on AI supporting regulatory decision-making in January 2025. In January 2026, the FDA and European Medicines Agency published joint guiding principles for good AI practice that put human oversight at the center of AI deployment.

 

Weave and Takeda say their approach follows the same principle: AI handles labor-intensive tasks such as drafting, data extraction, source traceability and review support, while regulatory professionals remain responsible for verification, content and final decisions.